MDMB-FUBINACA

Add links
Source: Wikipedia, the free encyclopedia.
MDMB-FUBINACA
Legal status
Legal status
Identifiers
  • Methyl (2S)-2-{[1-(4-fluorobenzyl)indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
JSmol)
  • O=C(N[C@H](C(OC)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
  • InChI=1S/C22H24FN3O3/c1-22(2,3)19(21(28)29-4)24-20(27)18-16-7-5-6-8-17(16)26(25-18)13-14-9-11-15(23)12-10-14/h5-12,19H,13H2,1-4H3,(H,24,27)/t19-/m1/s1
  • Key:RFCDVEHNYDVCMU-LJQANCHMSA-N

MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an

CB1 receptor (Ki = 0.14 nM, EC50 = 2.42 nM).[4][5] The structure of MDMB-FUBINACA contains the amino acid, 3-methylvaline[6] or tert-leucine
methyl ester.

Side effects

There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold by 2015.[7] Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and subsequent testing confirmed that at least 1000 hospitalisations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015.[8][9]

Legal status

In the United States, MDMB-FUBINACA is a Schedule I controlled substance.[10]

As of October 2015, MDMB-FUBINACA is a controlled substance in Belarus, Russia,[11] and China.[12]

In July 2021 it was included in Table II-A of the list of prohibited drugs of Portugal.

See also

References

  1. PMID 29549157
    .
  2. ^ "MDMB-FUBINACA". Cayman Chemical. Retrieved 13 July 2015.
  3. S2CID 20136837
    .
  4. ^ WO 2009106982, Buchler IP et al, "Indazole Derivatives" 
  5. PMID 27421060
    .
  6. ^ 3-methylvaline
  7. S2CID 31838655
    .
  8. ^ "Выступление председателя ГАК, директора ФСКН России В.П. Иванова на заседании ГАК 6 октября 2014 г." (in Russian). Federal Drug Control Service of the Russian Federation. 6 October 2014. Archived from the original on 9 July 2015. Retrieved 24 June 2015.
  9. ^ I. Bulygina (21 October 2014). "Clinical presentations of intoxication by new psychoactive compound MDMB(N)-Bz-F. Thesis of The II Scientific and Practical Seminar 'Methodical, Organizational and Law Problems of Chemical and Toxicological Laboratories of Narcological Services', Moscow" (in Russian). Retrieved 13 July 2015.
  10. ^ "Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I". Drug Enforcement Administration.
  11. ^ "Очередная жертва спайса" (in Russian). Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from the original on 14 July 2015. Retrieved 13 July 2015.
  12. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=MDMB-FUBINACA&oldid=1168602556"